Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Motus GI Holdings to $6 from $10 but keeps an Overweight rating on the shares. The company’s Q3 results were just shy of expectations on the top line, but its clinical pipeline is on track for headway in both Pure Vu Gastro and the outpatient reimbursement trial, both of which should be tailwinds to the business, the analyst tells investors in a research note. O’Brien adds that he remains optimistic about the potential of Motus GI’s technology and continues to recommend the name to risk-tolerant investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MOTS:
- Motus GI Holdings reports Q3 EPS ($1.69), consensus ($1.88)
- Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update
- Motus GI to Release Third Quarter Results and Provide a Business Update on November 14
- Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
- Motus GI Granted a U.S. Patent for Prepless Colonoscopy Methods Embodied by the Pure-Vu® System